Autori: Berti B

Filtra

Data

Development of the “SMA NNE” a short neonatal neurological examination for newborns with spinal muscular atrophy

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry

Bulbar function in children with spinal muscular atrophy type 1 treated with nusinersen

Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy

Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome?

Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study

Patient reported outcome measure for upper limb in Duchenne muscular dystrophy: correlation with PUL2.0

Assessing Prevalence and Characteristics of Oro-bulbar Involvement in Children and Adults with SMA Type 2 and 3 Using a Multimodal Approach

Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na‹ve patients with spinal muscular atrophy and following switch from other therapies

Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function

Torna in alto